<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">David Wilkinson</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>University of Southampton</td>
</tr>
<tr>
<td class="label">Country</td>
<td>UK</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>80</td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>[Alzheimer's Disease](/diseases/alzheimers)</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>Clinical trials, Acetylcholinesterase</td>
</tr>
</table>
David Wilkinson
Overview
David Wilkinson is a leading researcher in the field of neurodegenerative diseases, affiliated with University of Southampton. Their research focuses on Clinical trials, Acetylcholinesterase, with particular emphasis on Alzheimer's Disease. With an h-index of 80, Wilkinson is among the most cited researchers in the neuroscience field[@google2026].
Wilkinson's work spans multiple aspects of neurodegeneration, contributing to our understanding of the molecular mechanisms that underlie diseases such as Alzheimer's Disease. Their research group has made significant contributions to the fields of Clinical trials, Acetylcholinesterase, publishing in high-impact journals including leading neuroscience journals.
...<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">David Wilkinson</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>University of Southampton</td>
</tr>
<tr>
<td class="label">Country</td>
<td>UK</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>80</td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>[Alzheimer's Disease](/diseases/alzheimers)</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>Clinical trials, Acetylcholinesterase</td>
</tr>
</table>
David Wilkinson
Overview
David Wilkinson is a leading researcher in the field of neurodegenerative diseases, affiliated with University of Southampton. Their research focuses on Clinical trials, Acetylcholinesterase, with particular emphasis on Alzheimer's Disease. With an h-index of 80, Wilkinson is among the most cited researchers in the neuroscience field[@google2026].
Wilkinson's work spans multiple aspects of neurodegeneration, contributing to our understanding of the molecular mechanisms that underlie diseases such as Alzheimer's Disease. Their research group has made significant contributions to the fields of Clinical trials, Acetylcholinesterase, publishing in high-impact journals including leading neuroscience journals.
Based at University of Southampton, Wilkinson collaborates with researchers across multiple institutions worldwide, working to advance therapeutic strategies for neurodegenerative conditions.
Research Focus
Disease Areas
- [Alzheimer's Disease](/diseases/alzheimers-disease)
Mechanisms of Interest
- Clinical trials
- Acetylcholinesterase
Programmatic Emphasis
Wilkinson's portfolio emphasizes mechanism-aware biomarker interpretation and translational hypothesis testing in Alzheimer's Disease[@long2019]. Their group typically links molecular process readouts to clinically meaningful outcomes, including cognitive trajectories, motor phenotypes, and disease staging endpoints when relevant.
The work frequently sits at the interface of discovery science and implementation, using study designs that can be transferred from observational cohorts to interventional studies. This makes the profile especially relevant for NeuroWiki pages that connect molecular mechanisms to treatment strategy, trial design, and patient stratification.
Methods and Data Strategy
Within the Clinical trials, Acetylcholinesterase domain, this research profile is most aligned with multimodal integration: combining imaging, biofluid, genomic, and clinical metadata to derive robust disease signatures. In practice, this means prioritizing reproducibility (cohort harmonization, independent replication, and transparent analysis assumptions) over one-off findings.
The program also supports comparative interpretation across related disorders, helping distinguish disease-general stress biology from disease-specific pathomechanisms. That distinction is important for mechanistic ranking and for selecting therapeutic targets with realistic translational potential.
Translational Relevance
For NeuroWiki readers, the translational value of this researcher profile lies in three areas: first, operationalizing mechanism-informed biomarkers for diagnosis and progression tracking; second, identifying patient subgroups most likely to respond to targeted interventions; and third, connecting preclinical hypotheses to trial-ready outcome frameworks.
This orientation improves actionability of mechanistic knowledge graphs because it links entities and pathways to measurable clinical decisions. Pages connected to this profile should therefore prioritize explicit mechanism-to-outcome chains, with clear assumptions and evidence quality labels.
Key Publications
[PubMed author search for David Wilkinson](https://pubmed.ncbi.nlm.nih.gov/?term=David+Wilkinson%5BAuthor%5D)[@google2026]
[Google Scholar author search for David Wilkinson](https://scholar.google.com/scholar?q=author%3A%22David+Wilkinson%22)[@google2026]
[Semantic Scholar profile search for David Wilkinson](https://www.semanticscholar.org/search?q=David+Wilkinson)[@google2026]
Recent Research
Recent PubMed-indexed publications (2024-present):
[Upregulation of TNFR2 Precedes TOX Expression by Exhausted T cells and Restricts Antitumor and Antiviral Immunity.](https://pubmed.ncbi.nlm.nih.gov/41269210/). Clinical cancer research : an official journal of the American Association for Cancer Research. 2026.
[Dizziness Directly Influences Postconcussion Symptoms and Is Predictive of Poorer Mental Health in UK Military Personnel: A Retrospective Analysis.](https://pubmed.ncbi.nlm.nih.gov/37773599/). The Journal of head trauma rehabilitation. 2024.
[Informed non-dissent for brain death testing in children: ethical and legal perspectives.](https://pubmed.ncbi.nlm.nih.gov/38367980/). Archives of disease in childhood. 2024.
[RNA aptamer reveals nuclear TDP-43 pathology is an early aggregation event that coincides with STMN-2 cryptic splicing and precedes clinical manifestation in ALS.](https://pubmed.ncbi.nlm.nih.gov/38443601/). Acta neuropathologica. 2024.
[High resolution diffusion imaging in the unfixed post-mortem infant brain at 7T.](https://pubmed.ncbi.nlm.nih.gov/40692625/). Imaging neuroscience (Cambridge, Mass.). 2024.
Collaborators and Research Network
Collaborator network pending enrichment.
Institutional Context
Primary institutional links: [University of Southampton](/institutions/university-of-southampton). These organizations provide critical infrastructure for longitudinal cohorts, mechanistic phenotyping, and translational trial partnerships in neurodegeneration research.
Open Questions and Future Directions
- How can Clinical trials, Acetylcholinesterase signals be standardized across cohorts and sites without losing disease-stage sensitivity?
- Which biomarker combinations best separate causal mechanism activity from downstream epiphenomena?
- What trial designs can most efficiently translate mechanistic findings in Alzheimer's Disease into clinically meaningful interventions?
External Links
- Google Scholar: [Search for David Wilkinson](https://scholar.google.com/scholar?q=author%3A%22David+Wilkinson%22)
- PubMed: [Author search for David Wilkinson](https://pubmed.ncbi.nlm.nih.gov/?term=David+Wilkinson%5BAuthor%5D)
See Also
- [Researchers and Institutions Index](/researchers)
- [Diseases Index](/diseases)
- [Mechanisms Index](/mechanisms)
References
Unknown, Google Scholar author search for David Wilkinson (2026)
[Unknown, Long and Holtzman, Alzheimer disease an update on pathobiology and treatment strategies 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/30617256/)